UVM Cancer Center, FDA Announce New Treatment for Pancreatic Cancer

UVM Cancer Center, FDA announce new treatment for pancreatic cancer

Cancer patients in Vermont and New York will soon have access to a new kind of treatment. The medication was just approved for pancreatic cancer patients, and thanks to a clinical trial, some people in our region have already gotten to use it.

Breakthrough cancer treatment being researched in Arizona receives FDA approval

The FDA approved Daraxonrasib, a promising new cancer pill researched in Scottsdale.

FDA approves landmark pancreatic cancer drug

It is not a cure, but it is the first treatment to substantially extend the lives of patients with pancreatic cancer.

Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field

On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This episode is available on Spotify, Apple Podcasts, and Youtube. The approval was […]

FDA approves drug providing hope for pancreatic cancer patients

The U.S. Food and Drug Administration approved a new drug offering hope for people with pancreatic cancer, which is one of the deadliest types of cancer.

F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer

F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer blair.newman Tue, 09/01/2026